Integra LifeSciences (IART) Q4 2024 earnings summary

Executive summary

• Q4 2024 revenue increased 11.5% year-over-year to $443 million, with adjusted EPS of $0.97, exceeding guidance; full-year revenue was $1.61 billion, up 4.5%, but organic sales declined 1.3% due to supply and quality holds.

• Adjusted EPS for 2024 was $2.56, down 17.4% from 2023, mainly due to supply challenges and compliance investments.

• Operational improvements included supply recovery, increased Integra Skin production, reduction in shipping holds, and successful Acclarent integration.

• Leadership transition with a new CEO and new Chief Quality and Regulatory Officer, plus a board Quality Committee.

• Strategic investments in compliance, supply chain, and manufacturing capacity to support future growth.

Financial highlights

• Q4 2024 revenue: $442.6M (+11.5% year-over-year); FY 2024 revenue: $1,610.5M (+4.5% year-over-year, -1.3% organic).

• Q4 adjusted EPS: $0.97 (+9.0% year-over-year); FY adjusted EPS: $2.56 (-17.4% year-over-year).

• Q4 adjusted EBITDA margin: 23.7% (down 160 bps); FY adjusted EBITDA margin: 20.0% (down 400 bps).

• Q4 adjusted gross margin: 65.2% (+50 bps); FY adjusted gross margin: 64.5% (-160 bps).

• FY operating cash flow: $129.4M; adjusted free cash flow conversion: 12.7%.

Outlook and guidance

• FY 2025 revenue guidance: $1.65B–$1.72B (2.4%–6.5% reported growth, 1.0%–5.0% organic); adjusted EPS: $2.41–$2.51.

• Q1 2025 revenue expected at $375M–$385M (1.6%–4.4% reported, -6.2% to -3.5% organic); adjusted EPS: $0.40–$0.45.

• Guidance includes assumptions for $60M–$120M in potential additional shipping holds and intermittent supply disruptions from compliance initiatives.

• Gross margin expected to decline ~70 bps; adjusted EBITDA margin to remain flat.

• Sequential revenue improvement expected through 2025 as supply issues are resolved.